INTRODUCTION

S
WCE 1958, v a n DESIGNS, MATERIALS, and techniques of insertion have been tested by the authors."' '4s a result of these studies, a caged lens prosthesis has been developed which offers some significant advantages over ball valve prostheses, particularly in the mitral area. Studies with the lenticular valve have been in progrgs since May, 1964, and minor improvements are being incorporated continuously in the present design.
Valve Description The valve consists of a titanium frame and a woven Teflon fixation ring. Within the frame is a silicone rubber lens-shaped dim. The Teflon tixation ring for the mitral prosthesis is attached to the titanium cage in the form of a ring; whereas, in the aortic valve the prosthesis is extended ra- dially to form a flange (Fig. 1 ) . The mitral and aortic valve sizes are listed in Table 1 . Mitral sizes 65 through 85 correspond to available StamEdwards mitral valve sizes for adults. The low profile feature of the lens valve makes it possible to provide two sizes larger than the largest available ball valve. The orifice size of the ball valve is Limited by the size of the cage necessary to accommodate the ball which protrudes into the left ventricle. The free-floating lenticular disc is held in position over the valve orifice by a cage formed by three titanium legs. The silicone rubber lens is reinforced by a thin titanium ring which is molded in place within the lens. The ring is 0.010 inches larger in diameter than the valve orifice eliminating the posibiity that the lens will be forced through the valve orifice during high closing pressurn. The reinforcing ring is necessary to obtain a maximum reduction of lens thickness and weight. In addition, a softer silicone rubber can be used. If the reinforcing ring is elim- The pressure gradient at the calculated theoretical optimum opening was only two to three mmHg higher than the gradient across the valve with no l e n~ in place. Laboratory Ez'aluation .Although the lens valve has been tested in experimental animals, these tets are difficult to evaluate because of the high incidence of clot formation on any prosthesis. However, animal experimentation has been of value in testing basic designs. The valves have been tested in over 60 dogs to date with survival up to three months (Fig. 2) . Valve function during the period of survival was normal as were pressure gradients a c r m the valve at m t .
Mechanical fatigue testing showed the valve frame and the lens to be mistant to wear after an equivalent of 15 years of function in the valve testing apparatus. There was a 0.5 per cent gain in weight in the lens shortly after being placed in the valve tester, but no significant change in the lens after t h i s time. In a static testing device, random lenses were subjected to a gradually increasing hydraulic prmure.
The lensg withstood 40 to 50 pounds per square inch pressure without ~p t u r e .
Ball and lens valves have been compared in a mechanical tester by a uniform motion cam. Fluid flow through the valves in the "mechanical heart" was monitored with an electromagnetic flow meter, and movement of the valve occluder (ball or lens) was recorded from the analog output of a reflected ultrasound "echo-ranging" instrument. Lens and ball valves were compared with respect to pressure gradients, flow velocities, regurgitation, and movement of the lens or ball during opening and closing of the valve. The lens consistently opened earlier than the ball, and flow through the lens valve began sooner. Closure of the lens was complete in 10 to 15 m c . ; whereas, the ball required 22 to 30 msec. at rates of 60 to 150 cyclg/min. Significantly more regurgitation was observed during the closure period of the ball valve as compared with the lens. Pressure gradients a c r m the valves during flow were 1 to 2 mmHg lower in the lens valve. The ultrasound recording indicated marked oscillation of the ball during the opening phase; whereas, the lens moved rapidly and smoothly to the limit of the cage.
The energy dissipated at the valve seat during dosure was calculated from the respective m a s of the ocduder and the velocity of movement obtained from the ultrasound tracings. .4t cycle r a m of 60 per min. the lens energy was one-third of ball energy (1270 ergs. compared with 3700 ergs.); whereas, at 100 cycles/min. the energy of the lens was 6,000 ergs. compared with 7,000 ergs. for the ball. The increased energy of lens closure at the higher rates is due to the fact that energy is a function of mass and velocity squared; and, although the lens mass is less than one-fourth that of the ball, the velocity of closure is much greater in the lens valve.
Divrln of the Chrn
Cineradiographic studies of implanted valves have been performed in dogs and humans. The lens was observed to travel parallel with the valve seat throughout its excursion. There was no tilting of the lens in any phase of the cardiac cycle. There was no bounce at the end of rapid opening and closing movements which confirms the ultrasound studies in the mechanical heart. The lens mitral valve showed no discernible obstruction of the aortic outflow tract when contrast material was injected into the left ventricle, nor did there appear to be any interference with aortic valve function.
Clinical Evaluation
It is felt that the low profile lens valve is particularly adapted for use in the mitral area. For this reason more lens valves have k e n placed in the mitral area than in the aortic, and much of the discussion will be on mitral valve replacements.
The complications of embolus, leak, infection, and red cell damage as they relate to prosthetic valves are well known.' T h g e can be brought to an irreducible minimum by careful attention to surgical principles. Leak and red cell damage are probably related. The one instance of decreased red cell survival in our combined prosthetic series was corrected by re-operation and dosure of a leak around an aortic valve prosthesis. Infection of a prosthesis is virtually synonymous with death, but prophylactic use of proper antibiotics and increased attention to the details of surgical techniques is reducing this complication. Embolus is the most perplexing complication because it is not necessarily related to poor surgical technique, and it can occur in a patient with an otherwise perfectly placed and functioning valve. The incidence of embolus is being reduced by gradually changing valve designs, surgical techniques, and regimens of anticoaplation. Fibrin formation has been noted on experimental valves within 12 hours, and there have been examples of massive thrombus formation on human mitral prosthem within 24 hours of placement. For these reasons warfarin (Coumadin) therapy is started immediately postoperatively. Twenty to 40 milligrams of warfarin (Coumadin) are given intramuscularly on the afternoon of surgery, the dose depending on the size of the patient and 
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the control prothrombin time. With this dose, the prothrombin time is usually within the therapeutic range of 20 per cent to 30 per cent in 24 to 48 hours. The incidence and degree of postoperative bleeding has been neither excessive nor bothersome.
For most single valve replacements the m i d valve is approached by way of the interatrial groove through a right thoracotomy incision. A vent is alwa!s placed in the left ventricle for purposa of blood removal during surgeq, the aspiration of residual air in the ventricle after valve placement, and cardiac decompression during cardiac support in the immediate recovery period.' When marked cardiac enlargement is present, the right sided approach may be modified to a transternal approach, or a midline sternotomy incision is used.
Mitral and a o r t i c valve holders have been constructed to aid in valve insertion. The mitral valve holder consists of a slotted polypropylene block which snaps in place in the valve ring (Fig. 3 ) . The block serves to hold the lens against the bottom of the cage to prevent snagging of fixation sutures on the open end of the cage lens. About 24 suture are used in the placement of each mitnl and aortic valve. ..\her positioning the valve and tying the first few sutures, the handle ma)-be removed from the plastic block to facilitate tying the remaining sutures. The block is removed with a hemostat when the valve is secured in place. Since the legs are in full view when the aortic prosthesis is being placed, it is not necesaq to hold the lens against the cage during insertion. The aortic valve holder consists of a simple handle which clamps in place over the open end of the legs of the valve cage. There has been no instance of stuck lens reported to date.
During the period of pump support of the recovering heart, a r t e r i a l pressure is continuously monitored with a strain gauge. The ventricular vent is clamped periodically to determine if an adequate systolic pressure can be recorded with the heart pumping against the pressure produced by the pump oxygenator. When cardiac action is adequate the pump is discontinued. If it is then felt that the patient is hypovolemic, blood is cautiously given intra-arterially from the oxygenator while the venous and arterial pressures are monitored. This blood i5 given in relatively small increments until the venous pmqure r i m and becomesstable at the control level. After the cannulae have been removed, blood is replaced on the venous side of the circulation according to measurable blood losw.5.
T o date, 600 valves have been manufactured and sold. Statistin are available on 95 w l v a placed in a collected series of 86 patient5 from 15 centen, which gives a Table  3 it can be seen that 67 valves have been placed in the mitral area, 10 in the aortic area, and there have heen nine double valve insertions. Five of these are mid-aortic and four mitral-tricuspid combinations.
Obviously the greatest interest in the lens valve has been for mitral valve replacement. There have been seven early and eight late deaths in the mitral valve series for a mortality rate of 10 per cent and 12 per cent respectively. The total mortality in the aortic valve replacements, early and late, is 30 per cent, and in the double valve replacements 44 per cent. These mortality figures at first glance might seem high, but it must be remembered that in many instances the valves were placed in poor risk patients as the initial attempt in the use of a new valve. In only a few instances can the cause of death be attributed to the valve per se. T h e r e have been three instances of sudden death in which no postmortem examination was obtained. The presumed cause of death was either cardiac arrhythmia or embolus. In two instances of mitral valve replacement, postmortem examination showed clotting of the valve, one of which was early and massive. The remainder of the deaths were due to cardiac failure, myocardial infarction, bronchopneumonia, drug toxicity, and hepatic failure, c a m not related to the valve itself. There are two reported leaks around the valve rim in patients s u~v i n g with aortic valves, and there is one reported instance of a small nonfatal embolus in a patient with a mitral valve. In this patient, and in one patient dying from clotting of a mitral valve no anticoagulants were given postop eratively. The longest survival to date has been 20 months. P m r e gradients across the valve at rest have been near normal.
In spite of fairly uniform succes and acceptance of p m n t ball valve prostheses, the search for a more perfect valve continues. Because of problems of cloning and infection with prosthem, some investigators are evaluating valve homografts.' Early function of these valves has been very satisfactory. There is, however, a definite advantage to having a wide range of p m thews readily available for insertion. It is felt that the low profile lens valve k particularly adapted for use in the mitral area. The ball valve prosthesis has been criticized as a replacement for the mitral valve on the basis that the cage bulk in the left ventricle causes cardiac irregularities, low output syndrome, and aortic outflow obstruction. It is hoped that these complications will be avoided by the reduced bulk of the lens mitral valve. In practice it has been possible to insert lens mitral valves with a larger orifice size than would have been possible with a ball valve in hearts with a small left ventricle.
It is felt that another advantage of the lens valve is its decreased weight. .As stated earlier, this reduces inertial force necesar) to start the lens through its range of motion, resulting in quicker and quieter valve action with less oscillation of the lens during the opening phase. There is also less regurgitant flow through the lens valve, and it is impossible for it to become stuck. The light weight lens exerts less force against the cage at each extreme of motion which should reduce the possibility of dehiscence of the valve. .A wide range of sizes is available in both the aortic and mitral valves to meet virtually every requirement. Thc clinical evaluation of the valve has been satisfactory to date with relatively f m deaths and complications attributable to the valve per se. SUMMARY 1. The laboratory and clinical evaluation of a free-floating caged lens valve of low profile design is d i s c w d .
2. The results of 95 valve placements in 86 patients are given, the longest survival being 20 months.
3. It is felt that the important features of this valve are the low profile, its light weight, the rapid action and lack of oscillation of the valve occluder, and its quieter action in situ. 
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